The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMDS 2026 | The role of allo-SCT in MDS: patient selection and emerging cellular therapies
In this roundtable discussion, Olatoyosi Odenike, MD, University of Chicago, Chicago, IL, Alain Mina, MD, Yale School of Medicine, New Haven, CT, Mohamed Kharfan-Dabaja, MD, MBA, Mayo Clinic, Jacksonville, FL, Amy DeZern, MD, MHS, Johns Hopkins University School of Medicine, Baltimore, MD, and Talha Badar, MD, Mayo Clinic, Rochester, MN, discuss the role of allogeneic stem cell transplantation (allo-SCT) in myelodysplastic syndromes (MDS). Dr Mina and Dr Badar debate transplantation in TP53-mutated MDS, while Dr DeZern discusses patient selection, including lower-risk MDS, and graft-versus-host disease prophylaxis with post-transplant cyclophosphamide (PTCy). Dr Kharfan-Dabaja highlights post-transplant maintenance strategies and the challenges of developing CAR T-cell therapies for myeloid malignancies. This roundtable discussion took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
